For US Healthcare Professionals

Welcome to the RheuMuseum

The science of SpA on exhibit

There have been significant advances in the understanding of the pathobiology of SpA in the past 2 decades.


Take a tour to explore exhibits on axSpA and PsA that delve into the clinical manifestations, pathobiology, and disease outcome measures used in clinical practice.

axSpA=axial spondyloarthritis;
PsA=psoriatic arthritis.

A deeper understanding of these topics may hold the key to raising the standard of care and optimizing outcomes for patients.1,2

RheuMuseum guided tour
Welcome to the RheuMuseum

Hello, and welcome to the RheuMuseum!

I’m your guide, Jack, and I’d like to invite you to take a tour of our spondyloarthritis exhibits.

Whether you choose axial spondyloarthritis or psoriatic arthritis, you’ll embark on a unique journey as you explore each exhibit.

First, you’ll gaze at the Gallery of Cytokines: a modern art exhibit of the key cells and cytokines involved in the pathobiology of axSpA or PsA.

Next, you’ll visit our hall of statues, which illustrates the clinical manifestations of disease.

Finally, you’ll experience our transformative sculptural collages depicting disease outcomes measures and their evolving importance in defining disease activity.

We welcome you to sign up to become a RheuMuseum member, so you can be the first to know about important educational updates.

Enjoy your time exploring the science of SpA on exhibit at the RheuMuseum.

Take your seats in the Animated Science Theatre

Uncover the mechanisms driving SpA diseases, including the role of IL-17A, IL-17F, TNF, and IL-23

Take the axSpA tour

Start tour

Take the PsA tour

Start tour

The RheuMuseum now has more to offer beyond axSpA & PsA

  1. Furst DE and Louie JA. Targeting inflammatory pathways in axial spondyloarthritis. Arthritis Res Ther. 2019;21(1):135
  2. Silvagni E, Missiroli S, Perrone M, et al. From bed to bench and back: TNF-α, IL-23/IL-17A, and JAK-dependent inflammation in the pathogenesis of psoriatic synovitis. Front Pharmacol. 2021;12:672515